| Tbio | Myocilin |
Secreted glycoprotein regulating the activation of different signaling pathways in adjacent cells to control different processes including cell adhesion, cell-matrix adhesion, cytoskeleton organization and cell migration. Promotes substrate adhesion, spreading and formation of focal contacts. Negatively regulates cell-matrix adhesion and stress fiber assembly through Rho protein signal transduction. Modulates the organization of actin cytoskeleton by stimulating the formation of stress fibers through interactions with components of Wnt signaling pathways. Promotes cell migration through activation of PTK2 and the downstream phosphatidylinositol 3-kinase signaling. Plays a role in bone formation and promotes osteoblast differentiation in a dose-dependent manner through mitogen-activated protein kinase signaling. Mediates myelination in the peripheral nervous system through ERBB2/ERBB3 signaling. Plays a role as a regulator of muscle hypertrophy through the components of dystrophin-associated protein complex. Involved in positive regulation of mitochondrial depolarization. Plays a role in neurite outgrowth. May participate in the obstruction of fluid outflow in the trabecular meshwork.
MYOC encodes the protein myocilin, which is believed to have a role in cytoskeletal function. MYOC is expressed in many occular tissues, including the trabecular meshwork, and was revealed to be the trabecular meshwork glucocorticoid-inducible response protein (TIGR). The trabecular meshwork is a specialized eye tissue essential in regulating intraocular pressure, and mutations in MYOC have been identified as the cause of hereditary juvenile-onset open-angle glaucoma. [provided by RefSeq, Jul 2008]
MYOC encodes the protein myocilin, which is believed to have a role in cytoskeletal function. MYOC is expressed in many occular tissues, including the trabecular meshwork, and was revealed to be the trabecular meshwork glucocorticoid-inducible response protein (TIGR). The trabecular meshwork is a specialized eye tissue essential in regulating intraocular pressure, and mutations in MYOC have been identified as the cause of hereditary juvenile-onset open-angle glaucoma. [provided by RefSeq, Jul 2008]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| GLAUCOMA 1, OPEN ANGLE, A | 3 | 0.0 | 0.0 |
| Glaucoma, Open-Angle | 11 | 0.0 | 0.0 |
| Liver Cirrhosis, Experimental | 769 | 0.0 | 0.0 |
| Disease | Target Count |
|---|---|
| Glaucoma | 239 |
| Myopia | 176 |
| Abnormal iris vasculature | 2 |
| GLAUCOMA 3, PRIMARY CONGENITAL, A | 4 |
| Glaucoma of childhood | 2 |
| Hydrophthalmos | 19 |
| Disease | Target Count | P-value |
|---|---|---|
| psoriasis | 6694 | 8.3e-51 |
| lung adenocarcinoma | 2716 | 2.2e-18 |
| ovarian cancer | 8520 | 1.7e-09 |
| medulloblastoma, large-cell | 6241 | 4.8e-05 |
| osteosarcoma | 7950 | 1.7e-03 |
| breast carcinoma | 1638 | 1.7e-03 |
| interstitial cystitis | 2312 | 1.0e-02 |
| ductal carcinoma in situ | 1745 | 2.0e-02 |
| fibroadenoma | 559 | 4.9e-02 |
| Disease | Target Count |
|---|---|
| Primary open angle glaucoma juvenile onset 1 | 2 |
| primary congenital glaucoma | 5 |
| primary open angle glaucoma | 16 |
| Disease | log2 FC | p |
|---|---|---|
| breast carcinoma | -1.900 | 1.7e-03 |
| ductal carcinoma in situ | -2.000 | 2.0e-02 |
| fibroadenoma | -2.400 | 4.9e-02 |
| interstitial cystitis | -1.900 | 1.0e-02 |
| lung adenocarcinoma | -2.300 | 2.2e-18 |
| medulloblastoma, large-cell | 1.200 | 4.8e-05 |
| osteosarcoma | 1.738 | 1.7e-03 |
| ovarian cancer | 1.200 | 1.7e-09 |
| psoriasis | -2.300 | 8.3e-51 |
| Species | Source | Disease |
|---|---|---|
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| Inparanoid OMA EggNOG | ||
| OMA EggNOG |
MRFFCARCCSFGPEMPAVQLLLLACLVWDVGARTAQLRKANDQSGRCQYTFSVASPNESSCPEQSQAMSV 1 - 70 IHNLQRDSSTQRLDLEATKARLSSLESLLHQLTLDQAARPQETQEGLQRELGTLRRERDQLETQTRELET 71 - 140 AYSNLLRDKSVLEEEKKRLRQENENLARRLESSSQEVARLRRGQCPQTRDTARAVPPGSREVSTWNLDTL 141 - 210 AFQELKSELTEVPASRILKESPSGYLRSGEGDTGCGELVWVGEPLTLRTAETITGKYGVWMRDPKPTYPY 211 - 280 TQETTWRIDTVGTDVRQVFEYDLISQFMQGYPSKVHILPRPLESTGAVVYSGSLYFQGAESRTVIRYELN 281 - 350 TETVKAEKEIPGAGYHGQFPYSWGGYTDIDLAVDEAGLWVIYSTDEAKGAIVLSKLNPENLELEQTWETN 351 - 420 IRKQSVANAFIICGTLYTVSSYTSADATVNFAYDTGTGISKTLTIPFKNRYKYSSMIDYNPLEKKLFAWD 421 - 490 NLNMVTYDIKLSKM 491 - 504 //
